198 related articles for article (PubMed ID: 20173309)
1. Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain.
Nishikawa Y; Sasaki A; Kuraishi Y
J Pharmacol Sci; 2010; 112(3):352-60. PubMed ID: 20173309
[TBL] [Abstract][Full Text] [Related]
2. Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats.
Barthel F; Urban A; Schlösser L; Eulenburg V; Werdehausen R; Brandenburger T; Aragon C; Bauer I; Hermanns H
Anesthesiology; 2014 Jul; 121(1):160-9. PubMed ID: 24598217
[TBL] [Abstract][Full Text] [Related]
3. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats.
Yoshikawa S; Oguchi T; Funahashi Y; de Groat WC; Yoshimura N
Eur Urol; 2012 Oct; 62(4):704-12. PubMed ID: 22341128
[TBL] [Abstract][Full Text] [Related]
4. Glycine transporter GlyT1, but not GlyT2, is expressed in rat dorsal root ganglion--Possible implications for neuropathic pain.
Schlösser L; Barthel F; Brandenburger T; Neumann E; Bauer I; Eulenburg V; Werdehausen R; Hermanns H
Neurosci Lett; 2015 Jul; 600():213-9. PubMed ID: 26101830
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain.
Takahashi Y; Hara K; Haranishi Y; Terada T; Obara G; Sata T
Pharmacol Biochem Behav; 2015 Mar; 130():46-52. PubMed ID: 25579325
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological differences between static and dynamic allodynia in mice with herpetic or postherpetic pain.
Sasaki A; Serizawa K; Andoh T; Shiraki K; Takahata H; Kuraishi Y
J Pharmacol Sci; 2008 Nov; 108(3):266-73. PubMed ID: 18987431
[TBL] [Abstract][Full Text] [Related]
7. Glycine transporter inhibitors: A new avenue for managing neuropathic pain.
Al-Khrasani M; Mohammadzadeh A; Balogh M; Király K; Barsi S; Hajnal B; Köles L; Zádori ZS; Harsing LG
Brain Res Bull; 2019 Oct; 152():143-158. PubMed ID: 31302238
[TBL] [Abstract][Full Text] [Related]
8. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model.
Haranishi Y; Hara K; Terada T; Nakamura S; Sata T
Anesth Analg; 2010 Feb; 110(2):615-21. PubMed ID: 20081141
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Tyr1472 phosphorylation of NMDA receptor NR2B subunit in postherpetic neuralgia in model mice.
Unezaki S; Sasaki A; Mabuchi T; Matsumura S; Katano T; Nakazawa T; Nishio N; Andoh T; Yamamoto T; Nakatsuka T; Kuraishi Y; Ito S
Mol Pain; 2012 Aug; 8():59. PubMed ID: 22909213
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity.
Núñez E; Martínez-Maza R; Geerlings A; Aragón C; López-Corcuera B
Neuropharmacology; 2005 Nov; 49(6):922-34. PubMed ID: 16143353
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain.
Hermanns H; Muth-Selbach U; Williams R; Krug S; Lipfert P; Werdehausen R; Braun S; Bauer I
Neurosci Lett; 2008 Nov; 445(3):214-9. PubMed ID: 18793697
[TBL] [Abstract][Full Text] [Related]
12. Different roles of nitric oxide synthase-1 and -2 between herpetic and postherpetic allodynia in mice.
Sasaki A; Mabuchi T; Serizawa K; Takasaki I; Andoh T; Shiraki K; Ito S; Kuraishi Y
Neuroscience; 2007 Dec; 150(2):459-66. PubMed ID: 17997045
[TBL] [Abstract][Full Text] [Related]
13. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice.
Morita K; Motoyama N; Kitayama T; Morioka N; Kifune K; Dohi T
J Pharmacol Exp Ther; 2008 Aug; 326(2):633-45. PubMed ID: 18448867
[TBL] [Abstract][Full Text] [Related]
14. Contribution of spinal galectin-3 to acute herpetic allodynia in mice.
Takasaki I; Taniguchi K; Komatsu F; Sasaki A; Andoh T; Nojima H; Shiraki K; Hsu DK; Liu FT; Kato I; Hiraga K; Kuraishi Y
Pain; 2012 Mar; 153(3):585-592. PubMed ID: 22197693
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological evidence of increased glycine receptor-mediated phasic and tonic inhibition by blockade of glycine transporters in spinal superficial dorsal horn neurons of adult mice.
Oyama M; Kuraoka S; Watanabe S; Iwai T; Tanabe M
J Pharmacol Sci; 2017 Mar; 133(3):162-167. PubMed ID: 28302446
[TBL] [Abstract][Full Text] [Related]
16. ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn.
Eckle VS; Antkowiak B
Neuroscience; 2013 Dec; 253():165-71. PubMed ID: 23994185
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling.
Cioffi CL
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34200954
[TBL] [Abstract][Full Text] [Related]
18. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice.
Kopec K; Flood DG; Gasior M; McKenna BA; Zuvich E; Schreiber J; Salvino JM; Durkin JT; Ator MA; Marino MJ
Biochem Pharmacol; 2010 Nov; 80(9):1407-17. PubMed ID: 20637735
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cyclooxygenase-2 and EP3 prostaglandin receptor in acute herpetic but not postherpetic pain in mice.
Takasaki I; Nojima H; Shiraki K; Sugimoto Y; Ichikawa A; Ushikubi F; Narumiya S; Kuraishi Y
Neuropharmacology; 2005 Sep; 49(3):283-92. PubMed ID: 15925391
[TBL] [Abstract][Full Text] [Related]
20. Relief of cancer pain by glycine transporter inhibitors.
Motoyama N; Morita K; Shiraishi S; Kitayama T; Kanematsu T; Uezono Y; Dohi T
Anesth Analg; 2014 Oct; 119(4):988-995. PubMed ID: 25076101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
